Improved treatment of nicotine addiction and emerging pulmonary drug delivery.

Nazrul Islam, Shafiqur Rahman

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Nicotine addiction remains the leading cause of death and disease in developed and developing nations and a major cause of mortality around the world. Currently, nicotine replacement therapies (NRTs), bupropion, and varenicline are approved by the regulatory agencies as first-line treatments for nicotine addiction. Emerging evidence indicates that varenicline and bupropion have some therapeutic limitations for treating nicotine addiction with oral route of administration. Thus, continued investigation of innovative drug delivery for nicotine addiction remains a critical priority. This review will discuss some novel strategies and future directions for pulmonary drug delivery, an emerging route of administration for smoking cessation. It is anticipated that the advancement of knowledge on pulmonary drug delivery will provide better management for nicotine addiction and other addictive disorders.

Original languageEnglish
Pages (from-to)123-132
Number of pages10
JournalDrug Discoveries and Therapeutics
Issue number3
StatePublished - Jun 2012


Dive into the research topics of 'Improved treatment of nicotine addiction and emerging pulmonary drug delivery.'. Together they form a unique fingerprint.

Cite this